1
FDA ApprovedL5 · FDA Approved
FDA-approved (as bremelanotide / Vyleesi) for hypoactive sexual desire disorder in premenopausal women. Activates melanocortin-4 receptors; mechanism distinct from PDE5 inhibitors. Used on-demand subcutaneously.
Best Peptides for Libido & Sexual Function
Peptides evaluated for sexual dysfunction — ranked by FDA approval and clinical data.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
The libido-peptide category is small. PT-141 (bremelanotide) is FDA approved for hypoactive sexual desire disorder in premenopausal women. Other melanocortin peptides have related pharmacology but serious safety concerns.
How we ranked: Ordered by: (1) FDA approval, (2) indication-specific trial data, (3) safety profile.
2
Research OnlyL3 · Emerging Clinical Evidence
Parent melanocortin peptide. Libido-enhancing effects were observed in early trials, which led to PT-141 derivation. Cardiovascular and dermatological safety concerns make melanotan II unsuitable for routine use.
Caveat: Significant safety concerns; not FDA approved.
Frequently Asked Questions
How is PT-141 different from Viagra?
PT-141 (bremelanotide) acts on central melanocortin receptors rather than peripheral blood flow. It addresses low sexual desire, while PDE5 inhibitors like sildenafil address erectile response. Different mechanisms; different indications.
Is PT-141 FDA approved?
Yes, as bremelanotide (brand name Vyleesi) for hypoactive sexual desire disorder in premenopausal women, approved in 2019.
Does melanotan II improve libido safely?
Melanotan II can increase libido but carries cardiovascular effects, nausea, darkening of nevi, and priapism risk. It is not FDA approved and is not recommended.